KEY CAPITAL CORP - KCPC STOCK NEWS

Key Capital Corporation (OTC PINK:KCPC) announced a 90% reduction in COVID-19 virus infectivity through an independent university study on its Immunitor HAP-V+ Immune Supplement. Developed over a decade ago, HAP-V+ supports immunity and has shown anecdotal success in alleviating respiratory infections among users in Asia and Africa.

While early lab results are promising, further regulatory approval requires extensive clinical trials, with an international team in place to advance these studies in late 2021. Additionally, HAP-V+ will be marketed under the name 24/7 Immune BODY starting May 2021.

Key Capital Corporation (OTC PINK: KCPC) announces the launch of MaxCellLife.com, focusing on innovative supplement and skincare products. Marketing Director Jennifer Reilly, with a robust background in PR from Young and Rubican and Hyatt Hotels, will spearhead this initiative. The product line includes:

• BODY: Anti-aging supplements that address nutrition, cellular energy, and immunity.
• FACE: Age-defying skincare without harmful ingredients.
• MIND: A dietary supplement targeting anxiety and stress.

Key Capital continues to prioritize the development of oral pill therapeutic vaccines.

Key Capital Corporation (OTC PINK:KCPC) has redefined its focus on advancing its partnered Immunitor therapeutic cancer vaccines, specifically targeting formal registrations. The Immunitor V5 Series has shown promising success, achieving over a 90% survival rate in liver cancer patients. Key Biotec will lead new research initiatives, supported by up to $30 million in funding. The company plans to generate revenue starting Q2 2021 through the launch of two dietary supplements. Additionally, efforts are underway to finalize delinquent accounts for OTC market quotation, enhancing trading visibility.

Key Capital Corporation (OTC PINK:KCPC) is poised to launch its innovative MaxCellLife MIND dietary supplement, which combines M.vaccae and ionic magnesium aimed at enhancing mental well-being. This product targets the booming $18 billion anxiety and stress market. The first 50,000 doses are ready, manufactured in Thailand. The launch coincides with the completion of their marketing website within ten days. Key Capital aims to advance its oral pill therapeutic vaccines in collaboration with Immunitor, including the FDA Orphan Drug Designated V5 for liver cancer.

Key Capital Corporation (OTC PINK:KCPC) has announced significant breakthroughs in oral pill vaccine development through its partnership with Immunitor. The company reported 90% effectiveness in coronavirus inactivation from ongoing studies. Immunitor has successfully conducted human clinical trials in HCC liver cancer and other diseases, with results published in leading journals. Key Capital emphasizes the importance of protecting its intellectual property amid increased interest in oral vaccines. The focus remains on the FDA Orphan Drug Designated V5 vaccine for liver cancer.

Key Capital Corporation (OTC PINK:KCPC) announces significant developments with its partner Immunitor, securing a full patent in China and refiling patent claims in the EU. These patents protect the core technology for their therapeutic vaccines and supplements. Notably, the Immunitor V5 vaccine, designated as an FDA Orphan Drug, has shown a remarkable 90% 12-month survival rate in late-stage liver cancer patients. Key Capital aims to advance this promising candidate while exploring marketing options for their products.

Key Capital Corporation (OTC PINK:KCPC) announces a collaboration with Immunitor Inc to accelerate clinical studies and regulatory approval for its FDA Orphan Drug designated Immunitor V5, aimed at treating liver cancer, primarily hepatocellular carcinoma (HCC). The treatment boasts a remarkable 90% 12-month response and survival rate in clinical trials, significantly higher than conventional therapies. Given the urgent need for effective liver cancer treatments, this innovative approach may provide substantial cost savings and reduced side effects compared to existing options.

Key Capital Corporation (OTC PINK:KCPC) has announced a licensing agreement with Immunitor to exclusively develop and commercialize oral tableted immunotherapeutics across North America, the EU, Australia, and New Zealand. This groundbreaking platform has shown success in treating serious diseases like cancer and HIV/AIDS, positioning itself in the growing prescription drug market predicted to exceed US$1,500 billion by 2026. While regulatory approvals are pending in larger markets, the company aims to leverage this innovative technology to enhance treatment options and patient outcomes.